Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.

Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.

Potential implication of residual viremia in patients on effective antiretroviral therapy.

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.

Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.

Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Plasma Level of Soluble ST2 in Chronically Infected HIV-1 Patients with Suppressed Viremia.

Residual Viremia in Treated HIV+ Individuals.

Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.

Rotavirus vaccine virus shedding, viremia and clearance in infants with severe combined immune deficiency.

One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients.

Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.

Characterization of Immune Failure by Monocyte Activation Phenotypes in HIV-Infected Patients Receiving Antiretroviral Therapy.

Importance of combined fibrosis indices in chronic hepatitis B patients with low viremia.

Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.

Suggest Documents

Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.

Potential implication of residual viremia in patients on effective antiretroviral therapy.

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.

Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.

Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Plasma Level of Soluble ST2 in Chronically Infected HIV-1 Patients with Suppressed Viremia.

Residual Viremia in Treated HIV+ Individuals.

Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy.

Rotavirus vaccine virus shedding, viremia and clearance in infants with severe combined immune deficiency.

One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.

HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients.

Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.

Characterization of Immune Failure by Monocyte Activation Phenotypes in HIV-Infected Patients Receiving Antiretroviral Therapy.

Importance of combined fibrosis indices in chronic hepatitis B patients with low viremia.

Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.

Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.

Recommend Documents

Follow Us